Interferon News and Research

RSS

Medivir seeks FDA approval for simeprevir

Medivir AB today announced that a new drug application has been filed with the U.S. Food and Drug Administration seeking approval for simeprevir.

30 Mar 2013

Research findings could lead to new treatments for lung disorders in premature babies

Researchers at Yale School of Medicine have made major discoveries that could lead to new treatments for lung disorders in premature babies. In a mouse study, the team located key molecules that switch on stress pathways in preterm lung disorders, and also found that when parts of these pathways were blocked with a pain drug, lung damage was prevented or reversed.

21 Mar 2013

Hepatitis C and HIV co-infection treatment: an interview with Prof Boecher, Boehringer Ingelheim

Chronic hepatitis C infection is one of the most frequent chronic infectious diseases worldwide. The WHO estimates that 150 million people worldwide are chronically infected with the hepatitis C virus (HCV).

20 Mar 2013

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

...

14 Mar 2013

NIH-sponsored comparative trial evaluates benefits of combination therapy and monotherapy in MS

People with multiple sclerosis (MS) who were treated with combination therapy did not see significant clinical benefit over those treated with single drug therapy, but combination therapy did reduce the development of new lesions, according to an international research team led by The Mount Sinai Medical Center.

12 Mar 2013

Combination of INF and glatiramer acetate does not reduce MS progression

A recent clinical trial found that interferonβ-1a (INF) and glatiramer acetate (GA), two of the most commonly prescribed drugs for multiple sclerosis (MS), provide no additional clinical benefit when taken together.

12 Mar 2013

Adrenocorticotropic hormone may help treat people with multiple sclerosis

A new study suggests that treatment with adrenocorticotropic hormone (ACTH) may be helpful for people whose multiple sclerosis (MS) is not well-controlled through their regular treatment. The study was released today and will be presented at the American Academy of Neurology's 65th Annual Meeting in San Diego, March 16 to 23, 2013.

11 Mar 2013

Study helps explain why viruses often spread through the brain in patchwork patterns

Viruses often spread through the brain in patchwork patterns, infecting some cells but missing others. New research at Washington University School of Medicine in St. Louis helps explain why. The scientists showed that natural immune defenses that resist viral infection are turned on in some brain cells but switched off in others.

8 Mar 2013

Gene cluster implicated in Behçet's disease

Scientists may have uncovered an underlying genetic susceptibility for Behçet's disease in East Asian patients.

5 Mar 2013

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

Interim study results from STARTversoTM 4 presented today at CROI+ show that 80 percent of hepatitis C (HCV) patients also infected with HIV achieved early treatment success with faldaprevir (BI 201335) combined with pegylated interferon and ribavirin (PegIFN/RBV).

5 Mar 2013

Synthetic progesterone birth control injections have vulnerability to certain infections: Research

Women who are pregnant or using synthetic progesterone birth control injections have a conspicuous vulnerability to certain infections including malaria, Listeria, HIV, and herpes simplex virus.

2 Mar 2013

Janssen submits simeprevir regulatory application in Japan to treat HCV

Medivir AB today announced that its partner Janssen now has submitted a regulatory application to the Japanese Ministry of Health & Welfare authorities seeking approval for simeprevir, administered with pegylated interferon (Peg-IFN) and ribavirin (RBV) for the treatment of genotype 1 chronic hepatitis C patients who are treatment naïve, prior non responders or relapsed following treatment with Peg-IFN with or without RBV.

22 Feb 2013

Immunotherapy could be answer to treating novel coronavirus

Investigation into the mechanism of action of the novelcoronavirus HCoV-EMC, which recently emerged in the Middle East, has revealed that although human bronchial epithelia are very susceptible to infection with the virus, interferon I and III were both able to significantly reduce its replication in cell culture.

20 Feb 2013

Interleukin-10 levels predict otitis media culprit

Research shows that high serum levels of interleukin-10 indicate that the likely cause of acute otitis media is infection with Streptococcus pneumoniae, as opposed to Haemophilus influenzae or Moraxella catarrhalis.

18 Feb 2013

Researchers describe novel antiviral property of cholesterol-25-hydroxylase

A team of UCLA-led researchers has identified a protein with broad virus-fighting properties that potentially could be used as a weapon against deadly human pathogenic viruses such as HIV, Ebola, Rift Valley Fever, Nipah and others designated "priority pathogens" for national biosecurity purposes by the National Institute of Allergy and Infectious Disease.

13 Feb 2013

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Metastatic renal cell carcinoma is a devastating disease. There are roughly 20-25,000 new cases per year in the United States and it is increasing for some reason.

12 Feb 2013

Sunitinib shows promise against metastatic renal cell carcinoma

Findings from clinical trial patients with metastatic renal cell carcinoma, a common kidney cancer, show they did not have accelerated tumor growth after treatment with sunitinib, in contrast to some study results in animals. Sunitinib is one of several drugs, either on the market or undergoing testing, that target blood vessel growth.

10 Feb 2013

Scientists identify specific cellular events that appear key to lupus

A team led by scientists at The Scripps Research Institute (TSRI) has identified specific cellular events that appear key to lupus, a debilitating autoimmune disease that afflicts tens of millions of people worldwide. The findings suggest that blocking this pathway in lupus-triggering cells could be a potent weapon against the disease.

5 Feb 2013

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Gilead Sciences, Inc. announced today its results of operations for the fourth quarter and full year 2012.

5 Feb 2013

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

Gilead Sciences today announced topline results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide sofosbuvir in combination with ribavirin (FISSION) and in combination with ribavirin and pegylated interferon (NEUTRINO) among treatment-naïve patients with chronic hepatitis C virus (HCV) infection.

5 Feb 2013

Interferon News and Research

Medivir seeks FDA approval for simeprevir

Research findings could lead to new treatments for lung disorders in premature babies

Hepatitis C and HIV co-infection treatment: an interview with Prof Boecher, Boehringer Ingelheim

Phase 1b study of olesoxime initiated in multiple sclerosis (MS) patients

NIH-sponsored comparative trial evaluates benefits of combination therapy and monotherapy in MS

Combination of INF and glatiramer acetate does not reduce MS progression

Adrenocorticotropic hormone may help treat people with multiple sclerosis

Study helps explain why viruses often spread through the brain in patchwork patterns

Gene cluster implicated in Behçet's disease

HCV and HIV co-infected patients achieve early treatment success with faldaprevir, PegIFN/RBV

Synthetic progesterone birth control injections have vulnerability to certain infections: Research

Janssen submits simeprevir regulatory application in Japan to treat HCV

Immunotherapy could be answer to treating novel coronavirus

Interleukin-10 levels predict otitis media culprit

Researchers describe novel antiviral property of cholesterol-25-hydroxylase

Metastatic renal cell carcinoma (mRCC) therapy: an interview with Charles A. Nicolette, Ph.D., CSO of Argos Therapeutics

Sunitinib shows promise against metastatic renal cell carcinoma

Scientists identify specific cellular events that appear key to lupus

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News